Laure Gossec Selected Research

Psoriatic Arthritis

8/2022	Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
7/2022	Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
7/2022	Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
6/2022	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
1/2022	Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
1/2022	Response to: 'Comment on: 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Gossec et al' by Wei et al.
1/2022	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
1/2022	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
11/2021	What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study.
11/2021	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laure Gossec Research Topics

Disease

45	Rheumatoid Arthritis 10/2022 - 07/2006
33	Pain (Aches) 07/2022 - 02/2006
26	Psoriatic Arthritis 08/2022 - 03/2012
24	Fatigue 11/2022 - 11/2014
21	Necrosis 01/2022 - 06/2010
18	Axial Spondyloarthritis 01/2022 - 09/2015
18	Rheumatic Diseases (Rheumatism) 12/2021 - 12/2006
15	Ankylosing Spondylitis 01/2022 - 10/2007
10	Arthritis (Polyarthritis) 07/2022 - 04/2012
9	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 07/2009
8	Infections 01/2022 - 01/2010
8	Osteoarthritis 10/2015 - 12/2005
6	Chronic Disease (Chronic Diseases) 01/2022 - 01/2017
6	Inflammation (Inflammations) 06/2018 - 07/2006
5	COVID-19 01/2022 - 01/2021
4	Spondylarthropathies 01/2019 - 02/2008
4	Knee Osteoarthritis 05/2014 - 02/2006
3	Joint Diseases (Joint Disease) 01/2022 - 06/2010
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 05/2009
3	Neoplasms (Cancer) 01/2020 - 05/2009
3	Back Pain (Backache) 01/2019 - 04/2012
2	Synovitis 01/2022 - 07/2015
2	Musculoskeletal Diseases (Musculoskeletal Disease) 01/2022 - 01/2019
2	Vasculitis (Vasculitides) 01/2022 - 12/2021
2	Obesity 12/2021 - 01/2019
2	Hypertension (High Blood Pressure) 01/2021 - 01/2016
2	Osteoporosis 01/2020 - 01/2020
2	Hip Fractures (Intertrochanteric Fractures) 01/2020 - 01/2009
2	Fibromyalgia (Fibrositis) 01/2019 - 01/2018
2	Autoimmune Diseases (Autoimmune Disease) 03/2012 - 05/2009
2	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 03/2012 - 06/2010
2	Hip Osteoarthritis (Coxarthrosis) 09/2009 - 07/2009
1	Breakthrough Infections 01/2022
1	Skin Manifestations 01/2022
1	Opportunistic Infections (Opportunistic Infection) 01/2022

Drug/Important Bio-Agent (IBA)

22	Biological ProductsIBA 11/2022 - 04/2010
18	C-Reactive ProteinIBA 03/2022 - 07/2006
18	Antirheumatic Agents (DMARD)IBA 01/2022 - 07/2006
14	ametantrone (HAQ)IBA 07/2022 - 07/2010
14	GlucocorticoidsIBA 01/2022 - 07/2006
13	Etanercept (Enbrel)FDA Link 01/2020 - 12/2006
12	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022 - 03/2010
10	Tumor Necrosis Factor InhibitorsIBA 01/2020 - 12/2006
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018 - 07/2006
9	secukinumabIBA 01/2022 - 09/2015
9	Abatacept (Orencia)FDA Link 01/2021 - 05/2009
8	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 07/2006
8	Adalimumab (Humira)FDA Link 12/2021 - 12/2006
8	Prostaglandins AIBA 01/2021 - 09/2016
7	Pharmaceutical PreparationsIBA 01/2022 - 05/2009
7	Rituximab (Mabthera)FDA Link 01/2021 - 01/2008
7	Infliximab (Remicade)FDA Link 01/2020 - 12/2006
6	golimumab FDA Link 01/2020 - 03/2012
5	sarilumabIBA 10/2022 - 06/2017
5	tocilizumab (atlizumab)FDA Link 01/2020 - 06/2010
5	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2007
4	guselkumabIBA 06/2022 - 01/2020
4	Ustekinumab (CNTO 1275)FDA Link 01/2022 - 09/2015
4	Guanosine Diphosphate (GDP)IBA 01/2021 - 11/2014
4	Certolizumab Pegol FDA Link 01/2020 - 03/2014
4	Biosimilar PharmaceuticalsIBA 01/2020 - 03/2014
3	upadacitinibIBA 08/2022 - 01/2020
3	InterleukinsIBA 01/2022 - 01/2020
3	Interleukin-12 (IL 12)IBA 01/2022 - 01/2020
3	HLA-B27 Antigen (HLA B27 Antigen)IBA 07/2021 - 01/2017
3	Janus Kinase InhibitorsIBA 01/2021 - 06/2017
3	1- hydroxy- 5,8- bis(2- ((2- hydroxyethyl)amino)ethylamino)- 9,10- anthracenedioneIBA 12/2020 - 04/2016
3	tofacitinibIBA 01/2020 - 03/2014
3	apremilastIBA 01/2018 - 09/2015
3	N-phthaloylglutamic acidIBA 10/2017 - 09/2016
2	bimekizumabIBA 07/2022 - 07/2022
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 12/2013
2	Antimalarials (Antimalarial Agents)IBA 01/2022 - 01/2020
2	VaccinesIBA 01/2022 - 01/2022
2	Oxygen (Dioxygen)IBA 12/2021 - 01/2021
2	ixekizumabIBA 12/2021 - 01/2020
2	Prednisolone (Predate)FDA LinkGeneric 12/2021 - 01/2021
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 07/2015
2	Leflunomide (Arava)FDA LinkGeneric 01/2020 - 06/2017
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2020 - 06/2017
2	GLPG0634IBA 01/2020 - 01/2020
2	Janus KinasesIBA 01/2020 - 06/2017
2	baricitinibIBA 01/2020 - 06/2017
2	clazakizumabIBA 01/2020 - 06/2017
2	Monoclonal AntibodiesIBA 01/2019 - 01/2018
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2018 - 12/2016
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2015 - 02/2006
2	Hyaluronic Acid (Hyaluronan)IBA 10/2015 - 02/2006
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2015 - 07/2006
2	Anti-Citrullinated Protein AntibodiesIBA 01/2014 - 12/2010
1	Lopinavir FDA Link 01/2022
1	Azithromycin (Zithromax)FDA LinkGeneric 01/2022

Therapy/Procedure

26	Therapeutics 01/2022 - 07/2006
6	Fitness Trackers 12/2021 - 01/2017
5	Replacement Arthroplasty 01/2016 - 12/2005
4	Biological Therapy 07/2021 - 12/2013
3	Injections 01/2020 - 02/2006
3	Aftercare (After-Treatment) 01/2019 - 10/2010
2	Contraindications 03/2012 - 05/2009
1	Self Medication 01/2022